0 Common Stock, par value $0.001 per share false true DE NASDAQ true Non-accelerated Filer 2021 Q3 --12-31 true false false 0001560258 2 4 true 4 0 45,559,765 4 0001560258 2020-05-01 2020-05-06 0001560258 2021-09-27 0001560258 2021-11-01 0001560258 us-gaap:NotesPayableOtherPayablesMember 2020-06-25 2020-07-02 0001560258 ecor:LincolnParkCapitalFundLLCMember 2020-03-01 2020-03-27 0001560258 us-gaap:NotesPayableOtherPayablesMember 2021-07-31 0001560258 us-gaap:NotesPayableOtherPayablesMember 2021-06-25 2021-07-02 0001560258 us-gaap:NotesPayableOtherPayablesMember 2020-07-02 0001560258 us-gaap:NotesPayableOtherPayablesMember 2021-07-02 0001560258 us-gaap:NoncontrollingInterestMember 2021-06-30 0001560258 us-gaap:ParentMember 2021-06-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001560258 us-gaap:RetainedEarningsMember 2021-06-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001560258 us-gaap:CommonStockMember 2021-06-30 0001560258 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001560258 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001560258 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001560258 2021-06-25 2021-07-02 0001560258 us-gaap:NoncontrollingInterestMember 2020-06-30 0001560258 us-gaap:ParentMember 2020-06-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001560258 us-gaap:RetainedEarningsMember 2020-06-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001560258 us-gaap:CommonStockMember 2020-06-30 0001560258 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001560258 us-gaap:ParentMember 2020-04-01 2020-06-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001560258 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001560258 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001560258 us-gaap:ParentMember 2021-04-01 2021-06-30 0001560258 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001560258 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001560258 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroOneMember 2021-01-01 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroThreeMember 2021-01-01 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroTwoMember 2021-01-01 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroMember 2021-01-01 2021-09-30 0001560258 ecor:ExercisePriceFiveAndSixtyEightMember 2021-01-01 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroThreeMember 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroTwoMember 2021-09-30 0001560258 2021-03-31 0001560258 ecor:ExercisePriceTwelvePointSixZeroOneMember 2021-09-30 0001560258 ecor:ExercisePriceTwelvePointSixZeroMember 2021-09-30 0001560258 2021-01-01 2021-03-31 0001560258 ecor:ExercisePriceFiveAndSixtyEightMember 2021-09-30 0001560258 country:GB 2020-01-01 2020-09-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember 2020-01-01 2020-09-30 0001560258 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001560258 us-gaap:ParentMember 2021-07-01 2021-09-30 0001560258 us-gaap:NoncontrollingInterestMember 2021-03-31 0001560258 us-gaap:ParentMember 2021-03-31 0001560258 us-gaap:ParentMember 2021-01-01 2021-03-31 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001560258 us-gaap:RetainedEarningsMember 2021-03-31 0001560258 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001560258 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001560258 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001560258 us-gaap:CommonStockMember 2021-03-31 0001560258 2021-07-01 2021-09-30 0001560258 ecor:LessorMember us-gaap:SubsequentEventMember 2021-10-05 0001560258 ecor:LessorMember us-gaap:SubsequentEventMember 2021-10-04 0001560258 2020-01-01 2020-09-30 0001560258 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001560258 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0001560258 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001560258 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001560258 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0001560258 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001560258 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001560258 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0001560258 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001560258 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001560258 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001560258 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001560258 2021-01-01 2021-09-30 0001560258 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001560258 ecor:OtherMember 2020-07-01 2020-09-30 0001560258 ecor:OtherMember 2021-07-01 2021-09-30 0001560258 country:GB 2020-07-01 2020-09-30 0001560258 country:GB 2021-07-01 2021-09-30 0001560258 ecor:OtherMember 2020-01-01 2020-09-30 0001560258 2020-01-01 2020-03-31 0001560258 2019-12-31 0001560258 ecor:PromissoryNoteMember ecor:PaycheckProtectionProgramMember ecor:CitibankNaMember 2020-05-01 2020-05-04 0001560258 ecor:StockPurchaseAgreementMember ecor:LincolnParkCapitalFundLLCMember 2020-03-27 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember 2021-01-01 2021-09-30 0001560258 ecor:ChannelTwoMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember 2021-07-01 2021-09-30 0001560258 ecor:StockPurchaseAgreementMember ecor:LincolnParkCapitalFundLLCMember 2021-01-01 2021-09-30 0001560258 ecor:RestrictedStockAndDeferredStockMember srt:MinimumMember 2021-01-01 2021-09-30 0001560258 ecor:RestrictedStockAndDeferredStockMember srt:MaximumMember 2021-01-01 2021-09-30 0001560258 country:US 2021-01-01 2021-09-30 0001560258 ecor:OtherMember 2021-01-01 2021-09-30 0001560258 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001560258 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001560258 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001560258 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001560258 ecor:RestrictedStockAndDeferredStockMember 2021-01-01 2021-09-30 0001560258 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001560258 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001560258 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0001560258 2020-07-05 2020-07-17 0001560258 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001560258 us-gaap:NoncontrollingInterestMember 2019-12-31 0001560258 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001560258 us-gaap:ParentMember 2020-07-01 2020-09-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001560258 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001560258 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001560258 us-gaap:CommonStockMember 2020-09-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001560258 us-gaap:RetainedEarningsMember 2020-09-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001560258 us-gaap:ParentMember 2020-09-30 0001560258 us-gaap:NoncontrollingInterestMember 2020-09-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember 2021-07-01 2021-09-30 0001560258 us-gaap:USTreasuryBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001560258 us-gaap:USTreasuryBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001560258 us-gaap:USTreasuryBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001560258 us-gaap:USTreasuryBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001560258 us-gaap:USTreasuryBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001560258 us-gaap:USTreasuryBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001560258 us-gaap:CommonStockMember 2019-12-31 0001560258 us-gaap:RetainedEarningsMember 2019-12-31 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001560258 us-gaap:ParentMember 2019-12-31 0001560258 country:GB 2021-01-01 2021-09-30 0001560258 2020-07-01 2020-09-30 0001560258 us-gaap:USTreasuryBondSecuritiesMember 2021-09-30 0001560258 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001560258 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001560258 2020-09-30 0001560258 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001560258 us-gaap:InventoryValuationAndObsolescenceMember 2020-12-31 0001560258 ecor:ChannelTwoMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-09-30 0001560258 ecor:ChannelTwoMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-01-01 2021-09-30 0001560258 us-gaap:SalesRevenueNetMember ecor:DepartmentOfVeteransAffairsAndDepartmentOfDefenseMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-07-01 2021-09-30 0001560258 us-gaap:SalesRevenueNetMember ecor:DepartmentOfVeteransAffairsAndDepartmentOfDefenseMember us-gaap:RevenueFromRightsConcentrationRiskMember 2020-07-01 2020-09-30 0001560258 ecor:DepartmentOfVeteransAffairsAndDepartmentOfDefenseMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-01-01 2021-09-30 0001560258 ecor:DepartmentOfVeteransAffairsAndDepartmentOfDefenseMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2020-01-01 2020-09-30 0001560258 us-gaap:SalesRevenueNetMember ecor:NationalHealthServiceMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-07-01 2021-09-30 0001560258 us-gaap:SalesRevenueNetMember ecor:NationalHealthServiceMember us-gaap:RevenueFromRightsConcentrationRiskMember 2020-07-01 2020-09-30 0001560258 ecor:NationalHealthServiceMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-01-01 2021-09-30 0001560258 ecor:NationalHealthServiceMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2020-01-01 2020-09-30 0001560258 ecor:ChannelTwoMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-07-01 2021-09-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-01-01 2021-09-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2020-01-01 2020-09-30 0001560258 ecor:ChannelTwoMember ecor:VadodFacilitiesMember srt:MinimumMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2021-01-01 2021-09-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember us-gaap:RevenueFromRightsConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-07-01 2021-09-30 0001560258 us-gaap:RestrictedStockMember 2020-12-31 0001560258 us-gaap:RestrictedStockMember 2021-09-30 0001560258 ecor:RestrictedStockAndDeferredStockMember 2020-12-31 0001560258 ecor:RestrictedStockAndDeferredStockMember 2021-09-30 0001560258 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001560258 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001560258 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001560258 us-gaap:ParentMember 2020-01-01 2020-03-31 0001560258 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001560258 us-gaap:CommonStockMember 2020-03-31 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001560258 us-gaap:RetainedEarningsMember 2020-03-31 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001560258 us-gaap:ParentMember 2020-03-31 0001560258 us-gaap:NoncontrollingInterestMember 2020-03-31 0001560258 us-gaap:CommonStockMember 2021-09-30 0001560258 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001560258 us-gaap:RetainedEarningsMember 2021-09-30 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001560258 us-gaap:ParentMember 2021-09-30 0001560258 us-gaap:NoncontrollingInterestMember 2021-09-30 0001560258 us-gaap:USTreasuryBondSecuritiesMember 2020-12-31 0001560258 us-gaap:CommonStockMember 2020-12-31 0001560258 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001560258 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001560258 2021-09-30 0001560258 2020-03-31 0001560258 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001560258 2020-12-31 0001560258 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001560258 us-gaap:RetainedEarningsMember 2020-12-31 0001560258 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001560258 us-gaap:ParentMember 2020-12-31 0001560258 us-gaap:NoncontrollingInterestMember 2020-12-31 0001560258 2020-01-01 2020-12-31 0001560258 2021-04-01 2021-06-30 0001560258 2020-04-01 2020-06-30 0001560258 2020-06-30 0001560258 us-gaap:InventoryValuationAndObsolescenceMember 2021-09-30 0001560258 country:US 2021-07-01 2021-09-30 0001560258 2021-06-30 0001560258 country:US 2020-07-01 2020-09-30 0001560258 country:US 2020-01-01 2020-09-30 0001560258 2021-06-01 2021-06-07 0001560258 srt:MinimumMember 2021-01-01 2021-09-30 0001560258 srt:MaximumMember 2021-01-01 2021-09-30 0001560258 us-gaap:CommonStockMember 2021-06-25 2021-07-02 0001560258 us-gaap:CommonStockMember 2021-07-02 0001560258 us-gaap:CommonStockMember 2021-08-01 2021-08-30 0001560258 ecor:ChannelOneMember ecor:VadodFacilitiesMember us-gaap:RevenueFromRightsConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0001560258 2021-09-01 2021-09-22 0001560258 us-gaap:CommonStockMember 2021-08-30 0001560258 ecor:StockPurchaseAgreementMember ecor:LincolnParkCapitalFundLLCMember 2020-01-01 2020-12-31 0001560258 us-gaap:CommonStockMember 2021-09-27 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares ecor:facility

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One) |
☒ |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD EN DED September 30, 2021

☐ |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ______________ TO ______________

Commission File Number 001-38538

electroCore, Inc.

(Exact name of Registr ant as specified in its charter)

Delaware |  | 20-3454976
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

200 Forge Way, Suite 205, Rockaway, NJ 07866

(Address of principal executive offices, including zip code)

(973) 290-0097

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.001 per share |  | ECOR |  | The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter p eriod that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth com pany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ |  |  | Accelerated filer | ☐
Non-accelerated filer | ☒ |  |  | Smaller reporting company | ☒
Emerging growth company | ☒ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standard s provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of November 1, 2021 the registrant had 70,697,680 shares of common stock outstanding.

1

​

2

REFERENCES TO ELECTROCORE

In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to the “Company,” “electroCore,” “we,” “us” and “our” refer to electroCore, Inc. a Delaware corporation, and its subsidiaries and affiliate.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to them. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, (i) risks and uncertainties related to the impact of the COVID-19 pandemic on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate the COVID-19 pandemic, such as travel bans, vaccine mandates, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chains and patient access to commercial products; our ability to execute our operational and budget plans in light of the COVID-19 pandemic, and (ii) those included in our Form 10-Qs, our Annual Report on Form 10-K for the year ended December 31, 2020, in our other filings with the U.S. Securities and Exchange Commission or in materials incorporated by reference therein, including the information in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in such filings. Furthermore, any such forward-looking statements in this Quarterly Report speak only as of the date of this report. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of such statements.

The electroCore logo, gammaCore and other trademarks of electroCore, Inc. appearing in this Quarterly Report are the property of electroCore, Inc. All other trademarks, service marks and trade names in this Quarterly Report are the property of their respective owners. We have omitted the ® and ™ designations, as applicable, for the trademarks used in this Quarterly Report.

3

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Condensed Consolidated Balance Sheets
(Unaudited)

|  | September 30, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Assets |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 37,995,008 |  |  | $ | 4,241,937 |
Marketable securities |  |  | 1,001,080 |  |  |  | 18,386,160 |
Accounts receivable, net |  |  | 329,778 |  |  |  | 270,546 |
Inventories, net |  |  | 1,082,325 |  |  |  | 876,436 |
Prepaid expenses and other current assets |  |  | 1,476,348 |  |  |  | 1,288,588 |
Total current assets |  |  | 41,884,539 |  |  |  | 25,063,667 |
Inventories, noncurrent |  |  | 4,349,009 |  |  |  | 4,865,181 |
Property and equipment, net |  |  | 171,028 |  |  |  | 244,047 |
Operating lease right of use assets |  |  | 539,728 |  |  |  | 517,257 |
Other assets, net |  |  | 626,445 |  |  |  | 828,011 |
Total assets |  | $ | 47,570,749 |  |  | $ | 31,518,163 |
Liabilities and Equity |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,250,534 |  |  | $ | 2,078,699 |
Accrued expenses and other current liabilities |  |  | 4,429,843 |  |  |  | 2,965,702 |
Note payable, current |  |  | — |  |  |  | 311,354 |
Current portion of operating lease liabilities |  |  | 58,482 |  |  |  | 534,547 |
Total current liabilities |  |  | 5,738,859 |  |  |  | 5,890,302 |
Noncurrent liabilities: |  |  |  |  |  |  |  |
Operating lease liabilities, noncurrent |  |  | 715,530 |  |  |  | 885,333 |
Note payable, noncurrent |  |  | — |  |  |  | 1,097,946 |
Total liabilities |  |  | 6,454,389 |  |  |  | 7,873,581 |
Commitments and contingencies |  |  | — |  |  |  | — |
Stockholders' equity: |  |  |  |  |  |  |  |
Preferred Stock, par value $0.001 per share; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020 |  |  | — |  |  |  | — |
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at September 30, 2021 and December 31, 2020; 70,442,309 shares issued and outstanding at September 30, 2021 and 45,559,765 shares issued and outstanding at December 31, 2020 |  |  | 70,442 |  |  |  | 45,560 |
Additional paid-in capital |  |  | 159,796,442 |  |  |  | 130,205,027 |
Accumulated deficit |  |  | (119,261,417 | ) |  |  | (106,990,148 | )
Accumulated other comprehensive loss |  |  | (124,717 | ) |  |  | (251,467 | )
Total stockholders' equity |  |  | 40,480,750 |  |  |  | 23,008,972 |
Noncontrolling interest |  |  | 635,610 |  |  |  | 635,610 |
Total equity |  |  | 41,116,360 |  |  |  | 23,644,582 |
Total liabilities and equity |  | $ | 47,570,749 |  |  | $ | 31,518,163 |

See accompanying notes to unaudited condensed consolidated financial statements.

4

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Condensed Consolidated Statements of Operations

(Unaudited)

| Three months ended September 30, |  |  | Nine months ended September 30, |
| 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Net sales | $ | 1,487,093 |  |  | $ | 1,080,841 |  |  | $ | 3,960,401 |  |  | $ | 2,567,567 |
Cost of goods sold |  | 355,046 |  |  |  | 347,504 |  |  |  | 1,093,304 |  |  |  | 918,605 |
Gross profit |  | 1,132,047 |  |  |  | 733,337 |  |  |  | 2,867,097 |  |  |  | 1,648,962 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  | 470,275 |  |  |  | 629,002 |  |  |  | 1,794,146 |  |  |  | 3,182,646 |
Selling, general and administrative |  | 4,646,815 |  |  |  | 4,592,936 |  |  |  | 15,644,324 |  |  |  | 16,426,991 |
Restructuring and other severance related charges |  | — |  |  |  | — |  |  |  | — |  |  |  | 464,606 |
Total operating expenses |  | 5,117,090 |  |  |  | 5,221,938 |  |  |  | 17,438,470 |  |  |  | 20,074,243 |
Loss from operations |  | (3,985,043 | ) |  |  | (4,488,601 | ) |  |  | (14,571,373 | ) |  |  | (18,425,281 | )
Other (income) expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain on extinguishment of debt |  | — |  |  |  | — |  |  |  | (1,422,214 | ) |  |  | — |
Interest and other income |  | (3,834 | ) |  |  | (5,719 | ) |  |  | (8,493 | ) |  |  | (80,460 | )
Other expense |  | 3,771 |  |  |  | 3,522 |  |  |  | 7,293 |  |  |  | 13,350 |
Total other (income) expense |  | (63 | ) |  |  | (2,197 | ) |  |  | (1,423,414 | ) |  |  | (67,110 | )
Loss before income taxes |  | (3,984,980 | ) |  |  | (4,486,404 | ) |  |  | (13,147,959 | ) |  |  | (18,358,171 | )
(Provision) benefit from income taxes (see Note 14) |  | (8,705 | ) |  |  | — |  |  |  | 876,690 |  |  |  | 1,170,890 |
Net loss | $ | (3,993,685 | ) |  | $ | (4,486,404 | ) |  | $ | (12,271,269 | ) |  | $ | (17,187,281 | )
Net loss per share of common stock - Basic and Diluted (see Note 12) | $ | (0.06 | ) |  | $ | (0.10 | ) |  | $ | (0.22 | ) |  | $ | (0.47 | )
Weighted average common shares outstanding - Basic and Diluted (see Note 12) |  | 69,511,498 |  |  |  | 44,030,685 |  |  |  | 55,308,381 |  |  |  | 36,847,548 |

See accompanying notes to unaudited condensed consolidated financial statements.

5

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

| Three months ended September 30, |  |  | Nine months ended September 30, |
| 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Net loss | $ | (3,993,685 | ) |  | $ | (4,486,404 | ) |  | $ | (12,271,269 | ) |  | $ | (17,187,281 | )
Other comprehensive (loss) income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  | (22,282 | ) |  |  | (81,602 | ) |  |  | 124,366 |  |  |  | (145,617 | )
Unrealized gain (loss) on securities, net of taxes as applicable |  | 27 |  |  |  | (2,210 | ) |  |  | 2,384 |  |  |  | (3,443 | )
Other comprehensive (loss) income |  | (22,255 | ) |  |  | (83,812 | ) |  |  | 126,750 |  |  |  | (149,060 | )
Comprehensive loss | $ | (4,015,940 | ) |  | $ | (4,570,216 | ) |  | $ | (12,144,519 | ) |  | $ | (17,336,341 | )

See accompanying notes to unaudited condensed consolidated financial statements.

6

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Condensed Consolidated Statements of Equity

(Unaudited)

| Common |  |  | Additional |  |  |  |  |  |  | Accumulated other |  |  | Total electroCore, Inc. |  |  |  |  |  |  |  |  |
| Stock |  |  | paid-in |  |  | Accumulated |  |  | comprehensive |  |  | stockholders' |  |  | Noncontrolling |  |  | Total |
| Shares |  |  | Amount |  |  | capital |  |  | deficit |  |  | income (loss) |  |  | equity |  |  | interest |  |  | equity |
Balances as of January 1, 2021 |  | 45,559,765 |  |  | $ | 45,560 |  |  | $ | 130,205,027 |  |  | $ | (106,990,148 | ) |  | $ | (251,467 | ) |  | $ | 23,008,972 |  |  | $ | 635,610 |  |  | $ | 23,644,582 |
Net loss |  | — |  |  |  | — |  |  |  | — |  |  |  | (5,383,832 | ) |  |  | — |  |  |  | (5,383,832 | ) |  |  | — |  |  |  | (5,383,832 | )
Other comprehensive income |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 144,144 |  |  |  | 144,144 |  |  |  | — |  |  |  | 144,144 |
Issuance of stock (see Note 11) |  | 2,750,000 |  |  |  | 2,750 |  |  |  | 6,917,600 |  |  |  | — |  |  |  | — |  |  |  | 6,920,350 |  |  |  | — |  |  |  | 6,920,350 |
Issuance of stock related to employee compensation plans, net of forfeitures |  | 17,599 |  |  |  | 18 |  |  |  | (18 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Settlement of accrued bonus |  | 165,413 |  |  |  | 165 |  |  |  | 399,832 |  |  |  | — |  |  |  | — |  |  |  | 399,997 |  |  |  | — |  |  |  | 399,997 |
Share based compensation |  | — |  |  |  | — |  |  |  | 942,183 |  |  |  | — |  |  |  | — |  |  |  | 942,183 |  |  |  | — |  |  |  | 942,183 |
Balances as of March 31, 2021 |  | 48,492,777 |  |  | $ | 48,493 |  |  | $ | 138,464,624 |  |  | $ | (112,373,980 | ) |  | $ | (107,323 | ) |  | $ | 26,031,814 |  |  | $ | 635,610 |  |  | $ | 26,667,424 |
Net loss |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,893,752 | ) |  |  | — |  |  |  | (2,893,752 | ) |  |  | — |  |  |  | (2,893,752 | )
Other comprehensive income |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,861 |  |  |  | 4,861 |  |  |  | — |  |  |  | 4,861 |
Issuance of stock related to employee compensation plans, net of forfeitures |  | 197,647 |  |  |  | 197 |  |  |  | (197 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Share based compensation |  | — |  |  |  | — |  |  |  | 837,973 |  |  |  | — |  |  |  | — |  |  |  | 837,973 |  |  |  | — |  |  |  | 837,973 |
Balances as of June 30, 2021 |  | 48,690,424 |  |  | $ | 48,690 |  |  | $ | 139,302,400 |  |  | $ | (115,267,732 | ) |  | $ | (102,462 | ) |  | $ | 23,980,896 |  |  | $ | 635,610 |  |  | $ | 24,616,506 |
Net loss |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,993,685 | ) |  |  | — |  |  |  | (3,993,685 | ) |  |  | — |  |  |  | (3,993,685 | )
Other comprehensive income |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (22,255 | ) |  |  | (22,255 | ) |  |  | — |  |  |  | (22,255 | )
Issuance of stock, net of related expenses (see Note 11) |  | 20,700,000 |  |  |  | 20,700 |  |  |  | 18,744,182 |  |  |  | — |  |  |  | — |  |  |  | 18,764,882 |  |  |  | — |  |  |  | 18,764,882 |
Issuance of stock to satisfy legal fee obligation (see Note 11) |  | 952,380 |  |  |  | 952 |  |  |  | 989,523 |  |  |  | — |  |  |  | — |  |  |  | 990,475 |  |  |  | — |  |  |  | 990,475 |
Issuance of stock related to employee compensation plan, net of forfeitures |  | 99,505 |  |  |  | 100 |  |  |  | (100 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Share based compensation |  | — |  |  |  | — |  |  |  | 760,437 |  |  |  | — |  |  |  | — |  |  |  | 760,437 |  |  |  | — |  |  |  | 760,437 |
Balances as of September 30, 2021 |  | 70,442,309 |  |  | $ | 70,442 |  |  | $ | 159,796,442 |  |  | $ | (119,261,417 | ) |  | $ | (124,717 | ) |  | $ | 40,480,750 |  |  | $ | 635,610 |  |  | $ | 41,116,360 |

See accompanying notes to unaudited condensed consolidated financial statements

7

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Condensed Consolidated Statements of Equity

(Unaudited)

| Common |  |  | Additional |  |  |  |  |  |  | Accumulated other |  |  | Total electroCore, Inc. |  |  |  |  |  |  |  |  |
| Stock |  |  | paid-in |  |  | Accumulated |  |  | comprehensive |  |  | stockholders' |  |  | Noncontrolling |  |  | Total |
| Shares |  |  | Amount |  |  | capital |  |  | deficit |  |  | income (loss) |  |  | equity |  |  | interest |  |  | equity |
Balances as of January 1, 2020 |  | 29,835,183 |  |  | $ | 29,835 |  |  | $ | 107,752,066 |  |  | $ | (83,479,098 | ) |  | $ | (41,295 | ) |  | $ | 24,261,508 |  |  | $ | 635,610 |  |  | $ | 24,897,118 |
Net loss |  | — |  |  |  | — |  |  |  | — |  |  |  | (7,959,349 | ) |  |  | — |  |  |  | (7,959,349 | ) |  |  | — |  |  |  | (7,959,349 | )
Other comprehensive income |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 51,148 |  |  |  | 51,148 |  |  |  | — |  |  |  | 51,148 |
Equity financing commitment fee* |  | 461,676 |  |  |  | 462 |  |  |  | (462 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Issuance of stock related to employee compensation plans, net of forfeitures |  | 124,568 |  |  |  | 125 |  |  |  | (125 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Share based compensation |  | — |  |  |  | — |  |  |  | 744,865 |  |  |  | — |  |  |  | — |  |  |  | 744,865 |  |  |  | — |  |  |  | 744,865 |
Balances as of March 31, 2020 |  | 30,421,427 |  |  | $ | 30,422 |  |  | $ | 108,496,344 |  |  | $ | (91,438,447 | ) |  | $ | 9,853 |  |  | $ | 17,098,172 |  |  | $ | 635,610 |  |  | $ | 17,733,782 |
Net loss |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,741,528 | ) |  |  | — |  |  |  | (4,741,528 | ) |  |  | — |  |  |  | (4,741,528 | )
Other comprehensive income |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (116,396 | ) |  |  | (116,396 | ) |  |  | — |  |  |  | (116,396 | )
Issuance of stock (see Note 11) |  | 8,028,372 |  |  |  | 8,028 |  |  |  | 7,823,507 |  |  |  | — |  |  |  | — |  |  |  | 7,831,535 |  |  |  | — |  |  |  | 7,831,535 |
Equity financing commitment fee* |  | 181,273 |  |  |  | 181 |  |  |  | (181 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Financing fees |  | — |  |  |  | — |  |  |  | (167,299 | ) |  |  | — |  |  |  | — |  |  |  | (167,299 | ) |  |  | — |  |  |  | (167,299 | )
Issuance of stock related to employee compensation plans, net of forfeitures |  | 184,073 |  |  |  | 184 |  |  |  | (184 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Share based compensation |  | — |  |  |  | — |  |  |  | 1,002,758 |  |  |  | — |  |  |  | — |  |  |  | 1,002,758 |  |  |  | — |  |  |  | 1,002,758 |
Balances as of June 30, 2020 |  | 38,815,145 |  |  | $ | 38,815 |  |  | $ | 117,154,945 |  |  | $ | (96,179,975 | ) |  | $ | (106,543 | ) |  | $ | 20,907,242 |  |  | $ | 635,610 |  |  | $ | 21,542,852 |
Net loss |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,486,404 | ) |  |  | — |  |  |  | (4,486,404 | ) |  |  | — |  |  |  | (4,486,404 | )
Other comprehensive income |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (83,812 | ) |  |  | (83,812 | ) |  |  | — |  |  |  | (83,812 | )
Issuance of stock (see Note 11) |  | 6,079,676 |  |  |  | 6,080 |  |  |  | 11,197,581 |  |  |  | — |  |  |  | — |  |  |  | 11,203,661 |  |  |  | — |  |  |  | 11,203,661 |
Equity financing commitment fee* |  | 49,565 |  |  |  | 49 |  |  |  | (49 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Financing fees |  | — |  |  |  | — |  |  |  | (23,199 | ) |  |  | — |  |  |  | — |  |  |  | (23,199 | ) |  |  | — |  |  |  | (23,199 | )
Issuance of stock related to employee compensation plans, net of forfeitures |  | 254,702 |  |  |  | 255 |  |  |  | (255 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Share based compensation |  | — |  |  |  | — |  |  |  | 742,928 |  |  |  | — |  |  |  | — |  |  |  | 742,928 |  |  |  | — |  |  |  | 742,928 |
Balances as of September 30, 2020 |  | 45,199,088 |  |  | $ | 45,199 |  |  | $ | 129,071,951 |  |  | $ | (100,666,379 | ) |  | $ | (190,355 | ) |  | $ | 28,260,416 |  |  | $ | 635,610 |  |  | $ | 28,896,026 |

* | Reflects commitment shares issued in accordance with the Company's equity facility purchase agreement with Lincoln Park. For additional information see Note 11. Lincoln Park Stock Purchase Agreement.

8

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Condensed Consolidated Statements of Cash Flows

(Unaudited)

|  | Nine months ended September 30, |
|  | 2021 |  |  | 2020 |
|  |  |  |  | (revised) |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net loss |  | $ | (12,271,269 | ) |  | $ | (17,187,281 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Stock-based compensation |  |  | 2,540,593 |  |  |  | 2,490,551 |
Depreciation and amortization |  |  | 286,448 |  |  |  | 288,589 |
Amortization of marketable securities discount |  |  | 141,159 |  |  |  | 23,422 |
Gain on extinguishment of debt |  |  | (1,422,214 | ) |  |  | — |
(Gain) loss on legal fee obligation settled with stock |  |  | (9,525 | ) |  |  | 156,434 |
Net noncash lease expense |  |  | 56,151 |  |  |  | 273,070 |
Inventory reserve charge |  |  | 39,478 |  |  |  | — |
Other |  |  | — |  |  |  | 14,893 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable, net |  |  | (59,232 | ) |  |  | 320,186 |
Inventories |  |  | 270,805 |  |  |  | (15,922 | )
Prepaid expenses and other current assets |  |  | 703,257 |  |  |  | 561,248 |
Accounts payable |  |  | 171,835 |  |  |  | (1,631,839 | )
Accrued expenses and other current liabilities |  |  | 324,316 |  |  |  | (1,407,813 | )
Right of use operating leases |  |  | (78,622 | ) |  |  | — |
Operating lease liabilities |  |  | 33,277 |  |  |  | (355,274 | )
Net cash used in operating activities |  |  | (9,273,543 | ) |  |  | (16,469,736 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchase of marketable securities |  |  | (5,082,730 | ) |  |  | (22,166,376 | )
Proceeds from maturities of marketable securities |  |  | 22,300,000 |  |  |  | 10,500,000 |
Net cash provided by (used in) investing activities |  |  | 17,217,270 |  |  |  | (11,666,376 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Shares issued, net of related expenses |  |  | 25,685,232 |  |  |  | 17,139,563 |
Proceeds from note issued |  |  | — |  |  |  | 1,410,524 |
Net cash provided by financing activities |  |  | 25,685,232 |  |  |  | 18,550,087 |
Effect of changes in exchange rates on cash and cash equivalents |  |  | 124,112 |  |  |  | (145,312 | )
Net increase (decrease) in cash and cash equivalents |  |  | 33,753,071 |  |  |  | (9,731,337 | )
Cash and cash equivalents – beginning of period |  |  | 4,241,937 |  |  |  | 13,563,791 |
Cash and cash equivalents – end of period |  | $ | 37,995,008 |  |  | $ | 3,832,454 |
Supplemental cash flows disclosures: |  |  |  |  |  |  |  |
Proceeds from sale of state net operating losses |  | $ | 1,425,935 |  |  | $ | 1,170,890 |
Interest paid |  | $ | 4,649 |  |  | $ | 9,366 |
Income taxes paid |  | $ | 38,622 |  |  | $ | 3,254 |
Supplemental schedule of noncash activity: |  |  |  |  |  |  |  |
2020 Accrued bonus awarded in equity |  | $ | 399,997 |  |  | $ | — |
Accounts payable paid through issuance of common stock |  | $ | 1,000,000 |  |  | $ | 1,548,702 |

See accompanying notes to unaudited condensed consolidated financial statements.

9

ELECTROCORE, INC., SUBSIDIARIES AND AFFILIATE

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1. The Company

electroCore, Inc. (“electroCore” or the “Company”) is a medical device company, engaged in the commercialization and development of a platform non-invasive Vagus Nerve Stimulation (“nVNS”) therapy that can be self-administered by patients. electroCore was founded in 2005 and has primarily focused on primary headache conditions (migraine and cluster headache).

electroCore, headquartered in New Jersey, has two wholly owned subsidiaries: electroCore Germany GmbH, and electroCore UK Ltd. The Company has ceased its operations in Germany, although sales to Germany are still supported by electroCore UK Ltd.

Note 2. Summary of Significant Accounting Policies

(a) | Basis of Presentation

The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.

(b) | Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

(c) | Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns, valuation of inventory, stock compensation, and contingencies.

(d) | Revision of Statement of Cash Flows Activity

In preparation of its financial statements for the quarter ended March 31, 2021, the Company realized that proceeds from its July 1, 2020 Commercial Insurance Premium Finance and Security Agreement should have been treated as a noncash activity instead of grossed up on the accompanying condensed consolidated statement of cash flows. Even though the amount was not considered material, the financial statements have been revised. As a result, cash used in operating and cash provided by financing activities for the nine months ended September 30, 2020, decreased by approximately $600,000.

(e) | Reclassification of Statement of Cash Flows Activity

Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

10

Note 3. Significant Risks and Uncertainties

Liquidity

The Company has experienced significant net losses, and it expects to continue to incur net losses for the near future as it works to increase market acceptance of its gammaCore therapy for the acute treatment of episodic cluster headache (“eCH”), the prevention of cluster headache in adults, and the preventive and acute treatment of migraine in adults and adolescents. The Company has never been profitable and has incurred net losses in each year since its inception. The Company incurred net losses of $12.3 million and $17.2 million for the nine months ended September 30, 2021 and 2020, respectively.

The Company’s expected cash requirements for the next 12 months and beyond are largely based on the commercial success of its products. There are significant risks and uncertainties as to its ability to achieve these operating results, including as a result of the adverse impact on its headache business from the ongoing COVID-19 pandemic. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company has historically funded its operations from the sale of its common stock. During the nine months ended September 30, 2021, the Company received net proceeds of approximately $25.7 million from such sales and as of September 30, 2021, the Company’s cash, cash equivalents and marketable securities totaled $39.0 million. The Company believes that the substantial doubt of its ability to continue as a going concern is alleviated based on proceeds received from its common stock offerings. The Company believes its cash and marketable securities will enable it to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying financial statements are issued.

Concentration of Revenue Risks

The Company earns a significant amount of its revenue (i) in the United States from the Department of Veterans Affairs and Department of Defense pursuant to its qualifying contract under the Federal Supply Schedule and open market sales to individual Department of Veterans Affairs facilities and (ii) in the United Kingdom from the National Health Service. Each of these two channels accounted for 10% or more of the Company's net sales as summarized below:

|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2021 |  |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Revenue channel: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Department of Veterans Affairs and Department of Defense |  | 63.6% |  |  |  | 59.8% |  |  |  | 60.7% |  |  |  | 59.0% |
National Health Service |  | 24.1% |  |  |  | 24.2% |  |  |  | 25.6% |  |  |  | 28.1% |

During the three months ended September 30, 2021 and 2020 four and five specific VA/DoD facilities represented approximately 53.9% and 58.6% of the Company’s revenue from this channel, and two facilities accounted for more than 10% individually, respectively. During the nine months ended September 30, 2021 and 2020 four and three specific VA/DoD facilities represented approximately 52.1% and 41.0% of the Company’s revenue from this channel, and two facilities accounted for more than 10% individually, respectively.

Foreign Currency Exchange

The Company has foreign currency exchange risk related to revenue and operating expenses in currencies other than the local currencies in which it operates. The Company is exposed to currency risk from the potential changes in functional currency values of its assets, liabilities, and cash flows denominated in foreign currencies.

COVID-19 Risks and Uncertainties

The Company continues to monitor the impact of the coronavirus pandemic on all aspects of its business and geographies, including how it will impact business partners. While the Company experienced disruptions during the three and nine months ended September 30, 2021 and 2020 from the coronavirus pandemic, it is unable to predict the full impact that the coronavirus pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. COVID-19 has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. Depending upon the duration and severity of the pandemic, the continuing effect on the Company's results and outlook over the long term remains uncertain.

11

Note 4. Revenue Recognition

Geographical Net Sales

The following table presents net sales disaggregated by geographic area:

|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2021 |  |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Geographic Market |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
United States | $ | 1,103,604 |  |  | $ | 800,767 |  |  | $ | 2,810,152 |  |  | $ | 1,759,477 |
United Kingdom |  | 366,966 |  |  |  | 278,340 |  |  |  | 1,037,908 |  |  |  | 801,055 |
Other |  | 16,523 |  |  |  | 1,734 |  |  |  | 112,341 |  |  |  | 7,035 |
Total Net Sales | $ | 1,487,093 |  |  | $ | 1,080,841 |  |  | $ | 3,960,401 |  |  | $ | 2,567,567 |

Performance Obligations

Revenue, net of discounts, vouchers, rebates, returns, and co-payment assistance is solely generated from the sales of the gammaCore products. Revenue is recognized when delivery of the product is completed. The Company deems control to have transferred upon the completion of delivery because that is the point in which (1) it has a present right to payment for the product, (2) it has transferred the physical possession of the product, (3) the customer has legal title to the product, (4) the customer has risks and rewards of ownership and (5) the customer has accepted the product. After the products have been delivered and control has transferred, the Company has no remaining unsatisfied performance obligations.

12

Revenue is measured based on the consideration that the Company expects to receive in exchange for gammaCore, which represents the transaction price. The transaction price includes the fixed per-unit price of the product and variable consideration in the form of trade credits, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon distributor discount with the customer.

Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience. For the three and nine months ended September 30, 2021 and 2020, trade credits and discounts were immaterial.

Reimbursement for co-payments made by patients under the co-payment assistance program is considered variable consideration. Effective March 1, 2020, the amount of monthly co-payment assistance was reduced to a maximum of $100 per prescription. For the three and nine months ended September 30, 2021 and 2020, net sales reflect a reduction for the reduced cost of therapy under the co-payment assistance program. The calculation of the accrual is based on an estimate of claims and the cost per claim that the Company expects to incur associated with inventory that exists in the distribution channel at period end.

Managed care rebates represent our estimated obligations to pharmacy benefit managers. Rebate accruals are recognized in the same period the related revenue is recognized. Gross to net accruals based on estimated rebates were determined to be de minimis.

Contract Balances

The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Accordingly, under ASC 606, the Company’s contracts with customers did not give rise to contract assets or liabilities during the three and nine months ended September 30, 2021 and 2020.

Agreed upon payment terms with customers are within 120 days of shipment. Accordingly, contracts with customers do not include a significant financing component.

Note 5. Cash, Cash Equivalents and Marketable Securities

The following tables summarize the Company’s cash, cash equivalents and marketable securities as of September 30, 2021 and December 31, 2020.

As of September 30, 2021 |
|  | Amortized Cost |  |  | Unrealized Gain |  |  | Unrealized (Loss) |  |  | Fair Value |
Cash and cash equivalents |  | $ | 37,995,008 |  |  | $ | — |  |  | $ | — |  |  | $ | 37,995,008 |
Marketable securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bonds |  |  | 1,001,506 |  |  |  | — |  |  |  | (426 | ) |  |  | 1,001,080 |
Total cash, cash equivalents, and marketable securities |  | $ | 38,996,514 |  |  | $ | — |  |  | $ | (426 | ) |  | $ | 38,996,088 |

A s of December 31, 2020 |
|  | Amortized Cost |  |  | Unrealized Gain |  |  | Unrealized (Loss) |  |  | Fair Value |
Cash and cash equivalents |  | $ | 4,241,937 |  |  | $ | — |  |  | $ | — |  |  | $ | 4,241,937 |
Marketable securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bonds |  |  | 18,388,970 |  |  |  | — |  |  |  | (2,810 | ) |  |  | 18,386,160 |
Total cash, cash equivalents, and marketable securities |  | $ | 22,630,907 |  |  | $ | — |  |  | $ | (2,810 | ) |  | $ | 22,628,097 |

13

Note 6. Fair Value Measurements

Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy:

• | Level 1—Quoted prices in active markets for identical assets or liabilities.

• | Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

• | Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows:

|  |  |  |  |  | Fair Value Hierarchy |
September 30, 2021 |  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 37,995,008 |  |  | $ | 37,995,008 |  |  | $ | — |  |  | $ | — |
Marketable Securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. treasury bonds |  |  | 1,001,080 |  |  |  | 1,001,080 |  |  |  | — |  |  |  | — |
Total |  | $ | 38,996,088 |  |  | $ | 38,996,088 |  |  | $ | — |  |  | $ | — |

|  |  |  |  |  | Fair Value Hierarchy |
December 31, 2020 |  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 4,241,937 |  |  | $ | 4,241,937 |  |  | $ | — |  |  | $ | — |
Marketable Securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. treasury bonds |  |  | 18,386,160 |  |  |  | 18,386,160 |  |  |  | — |  |  |  | — |
Total |  | $ | 22,628,097 |  |  | $ | 22,628,097 |  |  | $ | — |  |  | $ | — |

The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the nine months ended September 30, 2021 and year ended December 31, 2020. The carrying amount of the Company’s receivables and payables approximate their fair values due to their short maturities.

Note 7. Inventories

As of September 30, 2021 and December 31, 2020, inventories consisted of the following:

|  | September 30, 2021 |  |  | December 31, 2020 |
Raw materials |  | $ | 820,227 |  |  | $ | 1,008,653 |
Work in process |  |  | 4,163,251 |  |  |  | 4,304,415 |
Finished goods |  |  | 447,856 |  |  |  | 428,549 |
Total inventories, net |  |  | 5,431,334 |  |  |  | 5,741,617 |
Less: noncurrent inventories |  |  | 4,349,009 |  |  |  | 4,865,181 |
Current inventories, net |  | $ | 1,082,325 |  |  | $ | 876,436 |

The reserve for obsolete inventory was $760,940 and $721,462 as of September 30, 2021 and December 31, 2020 respectively. The Company records charges for obsolete inventory in cost of goods sold. As of September 30, 2021 and December 31, 2020, noncurrent inventory was comprised of approximately $1.1 million and $0.7 million of raw materials, respectively, and $3.2 million and $4.2 million of work in process, respectively.

14

Note 8. Leases

For the three and nine months ended September 30, 2021, the Company recognized lease expense of $52,351 and $139,597, respectively, and $149,731 and $422,765 for the three and nine months ended September 30, 2020, respectively. This expense does not include non-lease components associated with the lease agreements as the Company elected not to include such charges as part of the lease expense.

On September 27, 2021, the Company entered into the Termination and Settlement Agreement ("Agreement") with the lessor associated with its former headquarters located in Basking Ridge, NJ. The Agreement provided for the immediate termination of the Basking Ridge lease in its entirety. In consideration for the lease termination, the Company agreed to pay the lessor a total of $500,000 in cash and issue to the lessor 200,000 shares of its common stock. As of September 30, 2021, the Company paid a total of $398,523 in cash to the lessor and accrued approximately $320,000 for the Company's remaining obligation under the Agreement. On October 4, 2021, the 200,000 shares of stock were issued to the lessor. On October 5, 2021, the Company paid to the lessor the remaining cash payment of $101,477.

The tables below provide the details of the right of use assets and lease liabilities as of September 30, 2021 and December 31, 2020:

|  | September 30, 2021 |  |  | December 31, 2020 |
Operating leases: |  |  |  |  |  |  |  |
Operating lease right of use assets |  | $ | 539,728 |  |  | $ | 517,257 |
Operating lease liabilities: |  |  |  |  |  |  |  |
Current portion of operating lease liabilities |  |  | 58,482 |  |  |  | 534,547 |
Noncurrent operating lease liabilities |  |  | 715,530 |  |  |  | 885,333 |
Total operating lease liabilities |  | $ | 774,012 |  |  | $ | 1,419,880 |
Weighted average remaining lease term (in years) |  |  | 7.3 |  |  |  | 5.7 |
Weighted average discount rate |  |  | 13.8 | % |  |  | 13.8 | %

Future minimum lease payments under non-cancellable operating leases as of September 30, 2021:

Remainder of 2021 |  | $ | 39,414 |
2022 |  |  | 160,486 |
2023 |  |  | 163,962 |
2024 |  |  | 167,524 |
2025 and thereafter |  |  | 704,900 |
Total future minimum lease payments |  |  | 1,236,286 |
Less: Amounts representing interest |  |  | (462,274 | )
Total |  | $ | 774,012 |

Note 9. Accrued Expenses and Other Current Liabilities

Accrued expenses as of September 30, 2021 and December 31, 2020 consisted of the following:

|  | September 30, 2021 |  |  | December 31, 2020 |
Accrued professional fees |  | $ | 166,050 |  |  | $ | 270,543 |
Accrued bonuses |  |  | 1,400,403 |  |  |  | 1,424,878 |
Accrued insurance expense |  |  | 873,592 |  |  |  | 164,832 |
Other employee related expenses |  |  | 425,067 |  |  |  | 371,033 |
Accrued state taxes |  |  | 548,705 |  |  |  | — |
Lease settlement liability |  |  | 320,000 |  |  |  | — |
Other |  |  | 696,026 |  |  |  | 734,416 |
|  | $ | 4,429,843 |  |  | $ | 2,965,702 |

15

Finance and Security Agreements
On July 2, 2021, the Company entered into a Commercial Insurance Premium Finance and Security Agreement ("the Agreement"). The 2021 Agreement provides for a single borrowing by the Company of $1.2 million, with a ten-month term and an annual interest rate of 1.55%. The proceeds from this transaction were used to partially fund the premiums due under certain of the Company's insurance policies. The amounts payable are secured by the Company's rights under such policies. The Company began to pay monthly installments of approximately $124,800 in July 2021. As of September 30, 2021, the remaining balance under the Agreement is $873,592 and during the three and nine months ended September 30, 2021, the Company recognized $2,646 in interest expense.
On July 1, 2020, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (“the 2020 Agreement”). The 2020 Agreement provided for a single borrowing by the Company of $1.2 million, with a seven-month term and an annual interest rate of 2.18%. The proceeds from this transaction were used to partially fund the premiums due under certain of the Company’s insurance policies. All borrowings related to the 2020 Agreement were fully repaid as of September 30, 2021.

Note 10. Notes Payable

Loan Under the PPP

On May 4, 2020, the Company received proceeds of $1.4 million in connection with a promissory note (the “Note”) entered into with Citibank, N.A. (the “Lender”) evidencing an unsecured loan (the “Loan”) under the Paycheck Protection Program ("PPP"). The PPP is a program of the Small Business Administration ("SBA") established under the CARES Act. Under the PPP, the proceeds of the Loan may be used for payroll and certain covered interest payments, lease payments and utility payments (“Qualifying Expenses”). The Company used the entire Loan amount for Qualifying Expenses under the PPP.

On May 18, 2021, the Company received notification from the Lender of SBA's approval of the Company's application for loan forgiveness. Accordingly, the Company is not required to repay the loan. The Company has recorded the loan forgiveness as a gain in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 under the caption Gain on extinguishment of debt.

Note 11. Stockholders’ Equity

Public Offering of Common Stock

On July 2, 2021, the Company completed a public offering of 20,700,000 shares of its common stock at a purchase price of $1.00 per share. The net proceeds of the offering to the Company were approximately $18.8 million, after deducting the underwriting discounts, commissions, and other offering expenses. The Company intends to use the net proceeds of the offering for sales and marketing, working capital, and general corporate purposes. While the Company has no current agreements or commitments for any specific acquisitions, in-licenses or investments at this time, it may use a portion of the net proceeds for these purposes.

Other Securities Purchase Agreements

On August 30, 2021, the Company entered into a Securities Purchase Agreement with its legal counsel pursuant to which the Company issued 952,380 shares of common stock, at a purchase price of $1.05 per share. Upon issuance of the shares, certain of the Company's outstanding financial obligations to its legal counsel were deemed paid and satisfied in full.

Lincoln Park Purchase Agreement

On March 27, 2020, the Company and Lincoln Park Capital Fund, LLC ("Lincoln Park") entered into an equity facility purchase agreement ("Purchase Agreement") pursuant to which the Company had the right to sell to Lincoln Park shares of its common stock having an aggregate value of up to $25,000,000, subject to certain limitations and conditions set forth in the Purchase Agreement.

Upon entering into the Purchase Agreement, the Company issued an aggregate of 461,676 shares of common stock to Lincoln Park as a commitment fee. The fair value of these shares on the date of issuance was approximately $186,300. During 2020, the Company issued an additional 230,838 shares of common stock to Lincoln Park as a further commitment fee based on the first $5,000,000 of shares of common stock issued to Lincoln Park under the Purchase Agreement as Purchase Shares (as such term is defined in the Purchase Agreement). T he Company did not receive any cash proceeds from the issuance of any of the foregoing commitment shares.

During 2020, the Company sold 10,179,676 shares of its common stock under the Purchase Agreement, resulting in aggregate proceeds of approximately $15.5 million to the Company. In January 2021, the Company sold an additional 2,750,000 shares of its common stock under the Purchase Agreement, resulting in aggregate proceeds of approximately $6.9 million to the Company. The Company expects to use the proceeds from this agreement for general corporate purposes and working capital. On March 11, 2021, the Company terminated the Purchase Agreement and, accordingly, the Company will not sell any further shares of its common stock to Lincoln Park under the Purchase Agreement.

16

Settlement of Accrued Bonus

In January 2021, the Company issued 165,413 shares of its common stock as payment for certain executive incentive bonuses accrued in 2020.

Settlement of Lease Liability

On September 27, 2021, the Company agreed to issue 200,000 shares of its common stock in connection with the lease termination related to its former headquarters located in Basking Ridge, NJ. As of September 30, 2021, these shares were not issued (see Note 8).

Note 12. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock and unit awards, stock options, and warrants have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect.

The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following:

|  | Nine months ended September 30, |
|  | 2021 |  |  | 2020 |
Outstanding stock options |  |  | 5,131,263 |  |  |  | 3,693,943 |
Nonvested restricted stock and unit awards |  |  | 1,153,364 |  |  |  | 1,230,651 |
Stock purchase warrants |  |  | 216,944 |  |  |  | 715,199 |
|  |  | 6,501,571 |  |  |  | 5,639,793 |

The following table presents a summary of stock purchase warrants outstanding at September 30, 2021:

Number of Warrants |  | Exercise Price | Expiration Date
22,253 | $ | 5.68 | 3/30/2022
17,066 | $ | 12.60 | 6/30/2022
151,364 | $ | 12.60 | 8/18/2022
14,286 | $ | 12.60 | 8/31/2022
11,975 | $ | 15.30 | 12/22/2025
216,944 |  |  |

During the nine months ended September 30, 2021, a total of 498,255 warrants expired. The exercise price of these warrants ranged between $8.86 and $12.60.

17

Note 13. Stock Based Compensation

The following table presents a summary of activity related to stock options during the nine months ended September 30, 2021:

| Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (Years) |  |  | Aggregate Intrinsic Value
Outstanding, January 1, 2021 |  | 3,815,585 |  |  | $ | 5.56 |  |  |  | 8.9 |  | $ | 342,551
Granted |  | 1,345,136 |  |  |  | 1.97 |  |  |  |  |  |  | 21,600
Exercised |  | — |  |  |  | — |  |  |  |  |  |  | —
Cancelled |  | (29,458 | ) |  |  | 5.22 |  |  |  |  |  |  | *
Outstanding, September 30, 2021 |  | 5,131,263 |  |  | $ | 4.62 |  |  |  | 8.2 |  | $ | 73,800
Exercisable, September 30, 2021 |  | 1,988,192 |  |  | $ | 7.67 |  |  |  | 7.6 |  | $ | 36,000

* de minimis

The intrinsic value is calculated as the difference between the fair market value at September 30, 2021 and the exercise price per share of the stock options. The options granted to employees generally vest over a four-year period.

The following table presents a summary of activity related to restricted stock awards (“RSAs”) granted during the nine months ended September 30, 2021:

|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value |  |
Nonvested, January 1, 2021 |  |  | 25,645 |  |  | $ | 10.07 |  |
Granted |  |  | 165,413 |  |  |  | 2.41 |  |
Vested |  |  | (149,894 | ) |  |  | 2.82 |  |
Cancelled |  |  | (5,687 | ) |  |  | 6.38 |  |
Nonvested, September 30, 2021 |  |  | 35,477 |  |  | $ | 2.82 |  |

In general, RSAs granted to employees vest over a four-year period.

18

The following table presents a summary of activity related to restricted and deferred stock units (“Stock Units”) granted during the nine months ended September 30, 2021:

|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value |
Nonvested, January 1, 2021 |  |  | 1,014,123 |  |  | $ | 1.50 |
Granted |  |  | 438,316 |  |  |  | 2.07 |
Vested |  |  | (329,198 | ) |  |  | 1.67 |
Cancelled |  |  | (5,354 | ) |  |  | 1.97 |
Nonvested, September 30, 2021 |  |  | 1,117,887 |  |  | $ | 1.67 |

In general, Stock Units granted to employees vest over two to four-year periods.

Immediately following the Company’s annual meeting of stockholders, the Company generally grants each non-employee director an equity award that vests over a 12-month period. Upon a non-employee director’s initial appointment or election to the board of directors, the Company grants such non-employee director an equity award subject to vesting as determined by the board of directors.

The Company recognized stock compensation expense for its equity awards as follows:

|  |  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Selling, general and administrative |  | $ | 658,314 |  |  | $ | 541,757 |  |  | $ | 2,171,122 |  |  | $ | 1,789,122 |
Research and development |  |  | 87,222 |  |  |  | 179,664 |  |  |  | 314,710 |  |  |  | 649,485 |
Cost of goods sold |  |  | 14,901 |  |  |  | 21,507 |  |  |  | 54,761 |  |  |  | 51,944 |
Total expense |  | $ | 760,437 |  |  | $ | 742,928 |  |  | $ | 2,540,593 |  |  | $ | 2,490,551 |

Total unrecognized compensation cost related to unvested awards as of September 30, 2021 was $5.1 million and is expected to be recognized over the next 2.2 years.

Valuation Information for Stock-Based Compensation

The fair value of each stock option award during the three and nine months ended September 30, 2021 and 2020 was estimated on the date of grant using the Black-Scholes model. For the nine months ended September 30, 2021, expected volatility was based on historical common stock volatility of the Company’s peers. Expected volatility for the nine months ended September 30, 2020, was based on historical volatility of the Company’s common stock. The risk-free interest rate was based on the average U.S. Treasury rate that most closely resembled the expected life of the related award. The expected term of the award was calculated using the simplified method. No dividend was assumed as the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the three and nine months ended September 30, 2021 and 2020 are summarized in the table below.

| Nine months ended September 30, |
| 2021 |  |  | 2020 |
Fair value at grant date | $ | 1.33 |  | $ | 0.98 |
Expected volatility | 80.2 | % |  | 142.1 | %
Risk-free interest rate | 0.7 | % |  | 0.7 | %
Expected holding period, in years | 6.0 |  |  | 6.1 |
Dividend yield |  | — | % |  | — | %

19

Note 14. Income Taxes

The Company may be eligible, from time to time, to receive cash from the sale of its net operating losses and research and development tax credits under New Jersey's Department of the Treasury - Division of Taxation NOL Transfer Program. On June 7, 2021, the Company received a net cash amount of approximately $1.4 million from the sale of its New Jersey state net operating losses and tax credits and recorded a tax benefit of approximately $880,000 in connection with this receipt. On September 22, 2021, the Company received notification from the New Jersey's Department of the Treasury - Division of Taxation requesting the return of an overpayment of approximately $549,000 related to the June 7, 2021 cash payment. The Company returned this overpayment on October 6, 2021. On May 6, 2020, the Company received a net cash amount of approximately $1.2 million from the sale of its New Jersey state net operating losses and research and development tax credits related to the year ended December 31, 2018. These sale proceeds are included in the Condensed Consolidated Statement of Operations for the nine months ended September 30, 2021 and September 30, 2020, under the caption Benefit from income taxes.

Note 15. Commitments and Contingencies

Stockholders Litigation

On July 8, 2019 and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to the Company, the defendants include present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for its IPO; and two of the Company’s stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which proceeded under Docket No. SOM-L 000876-19. Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased common stock in the IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees.

On October 31, 2019, the Company and the other defendants filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020, the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court – Appellate Division. The appeal was argued on September 27, 2021. On October 8, 2021, the Appellate Division issued an order reversing the decision of the Superior Court. The case has been remanded to the Superior Court for oral argument on the motion to dismiss or the alternative stay.

On September 26, 2019 and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to the Company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for the IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased the Company’s common stock in the IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each alleged that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints sought unspecified compensatory damages, interest, costs and attorneys’ fees.

In the Turnofsky case, on November 25, 2019 several plaintiffs and their counsel moved to be selected as lead plaintiff and lead plaintiff’s counsel. On April 24, 2020, the Court granted the motion of Carole Tibbs and the firm Bragar, Eagel & Squire, P.C. On July 17, 2020 the plaintiffs filed an amended complaint in Turnofsky. In addition to the prior claims, the amended complaint added an additional director defendant and two investors as defendants and adds a claim against the Company and the underwriters for violating Section 12(a)(2) of the Securities Act. On September 15, 2020, the Company and the other defendants filed a motion to dismiss the amended complaint for failure to state a claim. On November 6, 2020, the plaintiffs filed their opposition to the motion to dismiss. The Company and the other defendants filed reply papers in support of the motion on December 7, 2020. Argument of the motion to dismiss occurred on June 18, 2021. On August 13, 2021, the Court dismissed the amended complaint with leave to re-plead. On October 4, 2021, the plaintiffs filed a second amended complaint. The parties are participating in a non-binding mediation with JAMS. A session with the JAMS mediator occurred on March 30, 2021.

The Priewe case was voluntarily dismissed on February 19, 2020.

20

On March 4, 2021, purported stockholder Richard Maltz brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Richard Maltz, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al., Case 3:21-cv-04135. The defendants include present and past directors and officers of the Company. The plaintiff purports to pursue derivative claims on behalf of the Company in connection with the IPO and actions occurring between the IPO and September 25, 2019. The complaint alleges that demand on the board of directors is excused. The complaint purports to allege claims against the defendants for violating Section 14(a) of the Exchange Act, breaching fiduciary duties, unjust enrichment and waste of corporate assets. The complaint also purports to allege claims for contribution in connection with the Turnofsky case described above, pursuant to Section 11(f) of the Securities Act and Sections 10(b) and 21D of the Exchange Act. The complaint seeks unspecified compensatory damages, interest, costs and attorneys’ fees; declaratory relief; and an order requiring changes to corporate governance and internal procedures and a vote on proposed amendments to the Bylaws and Certificate of Incorporation. On March 8, 2021, purported stockholder Erin Yuson brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Erwin Yuson, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al., Case 3:21-cv-04481. The defendants include present and past directors and officers of the Company. The plaintiff purports to pursue derivative claims on behalf of the Company in connection with a 2019 proxy statement and actions occurring from the IPO through September 25, 2019. The complaint alleges that demand on the board of directors is excused. The complaint purports to allege claims against the defendants for violating Section 14(a) of the Exchange Act and breaching fiduciary duties. The complaint seeks unspecified compensatory damages, interest, costs and attorneys’ fees; declaratory relief; and an order requiring changes to corporate governance and internal procedures and a vote on proposed amendments to the Bylaws and Certificate of Incorporation.

The plaintiffs in the Maltz and Yuson derivative actions agreed to consolidate and stay those actions. The actions are stayed until and through the resolution of any motion for summary judgment in the Turnofsky federal securities class action. A stipulation to that effect was filed by the plaintiffs on April 14, 2021 and ordered by the court on April 30, 2021.

The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgments or settlements that could adversely affect the Company’s financial condition.

The Company expenses associated legal fees in the period they are incurred.

21

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

You should read this section in conjunction with our unaudited interim condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2020 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or SEC. As discussed in the section titled “Cautionary Note Regarding Forward-Looking Statements,” the following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those under the caption "Risk Factors" in the aforementioned Annual Report and this Form 10-Q.

Overview

We are a commercial-stage medical device company with a proprietary non-invasive vagus nerve stimulation, or nVNS, therapy. nVNS is a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. We are initially focused on neurology, and our therapy, gammaCore, is cleared by the FDA for use by adults for the following neurology indications: the acute treatment of pain associated with each of migraine and episodic cluster headache, or eCH, the preventive treatment of migraine headache and adjunctive use for the preventive treatment of cluster headaches, or CH. In February 2021, the FDA cleared the use of gammaCore for acute and preventive treatment of migraine in adolescents. In September 2021, the FDA cleared the use of gammaCore for the treatment of Paroxysmal Hemicrania (PH) and Hemicrania Continua (HC) in adults. PH and HC are rare forms of trigeminal autonomic cephalalgias that are typically debilitating and difficult to treat.

We are also considering the potential for several additional indications for our nVNS technology, which are being studied through several investigator-initiated studies. These indications include post traumatic headache, stroke, traumatic brain injury, post-traumatic stress disorder, opioid use disorders and post-operative ileus.

Our strategy has been to focus on selling gammaCore to treat different forms of primary headache upon regulatory approval. Following our initial FDA clearance in early 2017, our commercial strategy was to establish gammaCore as a first-line treatment option for the acute treatment of episodic CH in adult patients, who have few alternative treatment options available to them. This strategy was supported by a product registry conducted from July 2017 through June 2018 to build advocacy among key opinion leaders in leading headache centers in the United States, and to generate patient demand in the form of prescriptions submitted to payers. We leveraged this advocacy during the registry period as we expanded into migraine and prepared for a full commercial launch of gammaCore and gammaCore Sapphire for the acute treatment of pain associated with eCH and migraine in adult patients, which was accomplished in the third quarter of 2018. With the clearance of adjunctive use for the prevention of CH in December 2018, we continued to build upon our existing base of advocacy and patient support. In March 2020, the FDA cleared gammaCore for the preventive treatment of migraine headache in adult patients. In February 2021, gammaCore was cleared by the FDA for the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age.

Since May 2019, we have focused our sales efforts in two channels, the U.S. Department of Veterans Affairs and U.S. Department of Defense, and the United Kingdom.

We continue to evaluate strategies to expand commercial adoption of gammaCore, including the potential use of telemedicine and cash pay, direct to physician and consumer approaches. In future quarters, we expect to make targeted investments in the evaluation and possible execution of these strategies. We are unable to predict the impact these strategies will have on our financial condition, results of operations and cash flows due to numerous uncertainties.

Recently, we have announced agreements with new distributors to make gammaCore Sapphire available in several countries beyond the U.S. and United Kingdom.

22

Capital Activities

On July 2, 2021, we completed a public offering of 20,700,000 shares of our common stock at a purchase price of $1.00 per share. The net proceeds of the offering to us were approximately $18.8 million, after deducting the underwriting discounts and commissions and other estimated offering expenses. We intend to use the net proceeds of the offering for sales and marketing, working capital, and general corporate purposes. In addition, we believe that opportunities may exist from time to time to expand our current business through acquisitions or in-licenses of, or investments in, complementary companies, medicines, intellectual property, or technologies. While we have no current agreements or commitments for any specific acquisitions, in-licenses or investments at this time, we may use a portion of the net proceeds for these purposes.

On August 30, 2021, we entered into a Securities Purchase Agreement with our legal counsel pursuant to which we issued 952,380 shares of common stock, at a purchase price of $1.05 per share. Upon issuance of the shares, certain of our outstanding financial obligations to our legal counsel were deemed paid and satisfied in full.

Impact of COVID-19

We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and geographies, including how it will impact business partners. In particular, the pandemic has resulted in a significant reduction in non-essential contact between patients and healthcare providers, shifting of focus by healthcare providers to the acute treatment of COVID-19 related illness regardless of specialty. We believe these restrictions have limited our sales force’s ability to generate additional interest in the Company’s products. We are unable to predict the impact that the COVID-19 pandemic may have on our financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, the development, rollout and availability of effective treatments and vaccines, and the direct and indirect economic effects of the pandemic and containment measures, among others. The COVID-19 pandemic in many countries, including the United States, has significantly adversely impacted global economic activity. The global impact of the pandemic has been rapidly evolving and many countries have reacted by instituting quarantines, mandating business and school closures and restricting travel. The federal government, certain states and cities, including those where our principal place of business is located and sales force seeks to operate, have also reacted by instituting quarantines, vaccine mandates, restrictions on travel, “shelter in place” rules, and restrictions on types of business that may continue to operate. We cannot predict if the federal government or additional states and cities will implement similar or additional restrictions or when restrictions or mandates currently in place will expire. As a result, the COVID-19 pandemic is negatively impacting almost every industry directly or indirectly, including industries in which we operate. Further, the impacts of a potential worsening of global economic conditions and the continued disruptions to, and volatility in, the credit and financial markets, consumer spending as well as other unanticipated consequences remain unknown. See Item 1A. Risk Factors in this Form 10-Q, for discussion of certain risks associated with COVID-19 including the potential adverse effects on our workforce of the proposed U.S. Government vaccine mandate for employees, contractors, and subcontractors that service federal contracts. Additionally, see the section titled Risk Factors in our 2020 Annual Report on Form 10-K for discussion of risks related to COVID-19.

Because the COVID-19 pandemic affected, among other things, our access to prescribing physicians and their access to headache patients, we believe that our results for the nine months ended September 30, 2021 and 2020 reflect a negative impact from, among other things, the global pandemic. Moreover, our expectations for at least the remainder of 2021 have also been adversely affected by both the uncertainty and potential negative impact of the global pandemic. Depending upon the duration and severity of the pandemic, the continuing effect on our results and outlook over the long term remains uncertain.

In July 2020, the Company received an EUA for use of its gammaCore Sapphire CV nVNS therapy for the acute treatment of asthma exacerbations in known or suspected COVID-19 patients. This EUA is expected to remain in effect for the duration of the COVID-19 pandemic justifying emergency use of these devices unless terminated or revoked by the FDA (after which products may no longer be used). The length of the effective period of this EUA is uncertain. We did not recognize material revenue from the sales of gammaCore Sapphire CV during the nine months ended September 30, 2021 and we do not expect to recognize material revenue from the sales of gammaCore Sapphire CV in general.

23

Results of Operations

Comparison of the three months ended September 30, 2021 to the three months end ed September 30, 2020

The following table sets forth amounts from our condensed consolidated statements of operations for the three months ended September 30, 2021 and 2020:

|  | For the three months ended September 30, |  |  |  |  |
|  | 2021 |  |  | 2020 |  |  | Change |
|  | (in thousands) |
Consolidated statements of operations: |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 1,487.1 |  |  | $ | 1,080.9 |  |  | $ | 406.2 |
Cost of goods sold |  |  | 355.0 |  |  |  | 347.5 |  |  |  | 7.5 |
Gross profit |  |  | 1,132.1 |  |  |  | 733.4 |  |  |  | 398.7 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 470.3 |  |  |  | 629.1 |  |  |  | (158.8 | )
Selling, general and administrative |  |  | 4,646.8 |  |  |  | 4,592.9 |  |  |  | 53.9 |
Total operating expenses |  |  | 5,117.1 |  |  |  | 5,222.0 |  |  |  | (104.9 | )
Loss from operations |  |  | (3,985.0 | ) |  |  | (4,488.6 | ) |  |  | 503.6 |
Other (income) expense |  |  |  |  |  |  |  |  |  |  |  |
Interest and other income |  |  | (3.8) |  |  |  | (5.8 | ) |  |  | 2.0 |
Other expense |  |  | 3.8 |  |  |  | 3.6 |  |  |  | 0.2 |
Total other (income) expense |  |  | — |  |  |  | (2.2 | ) |  |  | 2.2 |
Loss before income taxes |  |  | (3,985.0 | ) |  |  | (4,486.4 | ) |  |  | 501.4 |
Provision for income taxes |  |  | (8.7 | ) |  |  | — |  |  |  | (8.7 | )
Net loss |  | $ | (3,993.7 | ) |  | $ | (4,486.4 | ) |  | $ | 492.7 |

Net Sales

Net sales increased 38% for the three months ended September 30, 2021 compared to the prior year period. This increase of $406.2 thousand is due to increased sales across all major channels including Commercial, the U.S. Department of Veteran Affairs, and in the United Kingdom, as well as sales from our new distributors outside of the United States. For the remainder of our 2021 fiscal year, we expect the majority of our revenue will come from the U.S. Department of Veterans Affairs and United Kingdom.

Gross Profit

Gross profit increased $398.7 thousand for the three months ended September 30, 2021 compared to the prior year period due to the increase in net sales. Gross margin was 76% and 68% for the three months ended September 30, 2021 and 2020, respectively. The increase in gross margin was largely due to increased sales resulting in a more favorable absorption of labor and overhead costs and product mix.

Research and Development

Research and development expense decreased by $158.8 thousand or 25% for the three months ended September 30, 2021 compared to the prior year period. This reduction was primarily due to significant reductions in investment in research and development offset by targeted investments to support certain investigator-initiated trials, scientific publications and product development.

Selling, General and Administrative

Selling, general and administrative expense was consistent with the prior year period. We expect an increase in our selling, general, and administrative expense for the remainder of our 2021 fiscal year as we may make targeted investments to support our commercial efforts.

24

Other (Income) Expense

Interest and other income of $3,834 and $5,719 for the three months ended September 30, 2021 and 2020, respectively, primarily consists of interest earned on cash, cash equivalents and marketable securities.

Comparison of the nine months ended September 30, 2021 to the nine months ended September 30, 2020

The following table sets forth amounts from our consolidated statements of operations for the nine months ended September 30, 2021 and 2020:

|  | For the nine months ended September 30, |  |  |  |  |
|  | 2021 |  |  | 2020 |  |  | Change |
|  | (in thousands) |
Consolidated statements of operations: |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 3,960.4 |  |  | $ | 2,567.6 |  |  | $ | 1,392.8 |
Cost of goods sold |  |  | 1,093.3 |  |  |  | 918.6 |  |  |  | 174.7 |
Gross profit |  |  | 2,867.1 |  |  |  | 1,649.0 |  |  |  | 1,218.1 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 1,794.1 |  |  |  | 3,182.7 |  |  |  | (1,388.6 | )
Selling, general and administrative |  |  | 15,644.3 |  |  |  | 16,427.0 |  |  |  | (782.7 | )
Restructuring and other severance related charges |  |  | — |  |  |  | 464.6 |  |  |  | (464.6 | )
Total operating expenses |  |  | 17,438.4 |  |  |  | 20,074.3 |  |  |  | (2,635.9 | )
Loss from operations |  |  | (14,571.3 | ) |  |  | (18,425.3 | ) |  |  | 3,854.0 |
Other (income) expense |  |  |  |  |  |  |  |  |  |  |  |
Gain on extinguishment of debt |  |  | (1,422.2 | ) |  |  | — |  |  |  | (1,422.2 | )
Interest and other income |  |  | (8.4 | ) |  |  | (80.5 | ) |  |  | 72.1 |
Other expense |  |  | 7.3 |  |  |  | 13.4 |  |  |  | (6.1 | )
Total other (income) expense |  |  | (1,423.3 | ) |  |  | (67.1 | ) |  |  | (1,356.2 | )
Loss before income taxes |  |  | (13,148.0 | ) |  |  | (18,358.2 | ) |  |  | 5,210.2 |
Benefit from income taxes |  |  | 876.7 |  |  |  | 1,170.9 |  |  |  | (294.2 | )
Net loss |  | $ | (12,271.3 | ) |  | $ | (17,187.3 | ) |  | $ | 4,916.0 |

Net Sales

Net sales increased 54% for the nine months ended September 30, 2021 compared to the prior year period. The increase of $1.4 million is due to increased sales across all major channels including Commercial, the U.S. Department of Veteran Affairs, and in the United Kingdom, as well as sales from our new distributors outside of the United States. For the remainder of our 2021 fiscal year, we expect the majority of our revenue will come from the U.S. Department of Veterans Affairs and United Kingdom.

Gross Profit

Gross profit increased $1.2 million for the nine months ended September 30, 2021 compared to the prior year. Gross margin increased to 72% for the nine months ended September 30, 2021 compared to 64% for the nine months ended September 30, 2020. These increased gross profits were largely due to increased sales resulting in more favorable absorption of labor and overhead costs and product mix.

25

Research and Development

Research and development expense decreased by $1.4 million or 44% for the nine months ended September 30, 2021 compared to the prior year period. This reduction was primarily due to significant reductions in investment in research and development including the early termination of our Premium II clinical trial, offset by the initial payment for an investigator-initiated study for the treatment of post-traumatic headache, and targeted investments to support certain investigator-initiated trials, scientific publications and product development.

Selling, General and Administrative

Selling, general and administrative expense was $15.6 million and $16.4 million for the nine months ended September 30, 2021 and 2020, respectively. The $782.7 thousand decrease was primarily due to cost reductions associated with the outbreak of the COVID-19 pandemic, offset by reinvestment in the commercial business as the pandemic began to subside. We expect an increase in our selling, general, and administrative expense for the remainder of our 2021 fiscal year as we may make targeted investments to support our commercial efforts.

Restructuring and Other Severance Related Charges

There were no restructuring and other severance related costs for the nine months ended September 30, 2021. Restructuring and other severance related costs for the nine months ended September 30, 2020 of $464,606 consisted of severance related expenses in connection with personnel changes.

Other (Income) Expense

Oth er (income) expense for the nine months ended September 30, 2021 primarily represents the gain of $1.4 million recorded by the Company in association with the forgiveness of its PPP loan. Interest and other income of $8,493 and $80,460 for the nine months ended September 30, 2021 and 2020, respectively, primarily consists of interest earned on cash, cash equivalents and marketable securities.

Benefit from Income Taxes

The benefit from income taxes of $0.9 million and $1.2 million for the nine months ended September 30, 2021 and 2020, respectively, represent the sale of our 2019 and 2018 state net operating losses and research and development tax credits under the State of New Jersey's NOL Transfer Program.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods noted below:

|  | For the nine months ended September 30, |
|  | 2021 |  |  | 2020 |
|  | (in millions) |
Net cash (used in) provided by |  |  |  |  |  |  |  |
Operating activities |  | $ | (9.3 | ) |  | $ | (16.5 | )
Investing activities |  | $ | 17.2 |  |  | $ | (11.7 | )
Financing activities |  | $ | 25.7 |  |  | $ | 18.6 |

Operating Activities

Net cash used in operating activities was $9.3 million and $16.5 million for the nine months ended September 30, 2021 and 2020, respectively. This favorable result is primarily due to a decrease in our net loss from operations, and less cash being used for working capital components such as inventory and accounts payable.

Investing Activities

Net cash provided by investing activities was $17.2 million for the nine months ended September 30, 2021 compared to $11.7 million used in investing activities for the nine months ended September 30, 2020, reflecting an increase in funds received from the maturity of marketable securities partially offset by a decrease in our purchases of marketable securities during the current period.

26

Financing Activities

Net cash provided by financing activities was $25.7 million for the nine months ended September 30, 2021, representing proceeds from the sale of common stock.

Liquidity Outlook

As of September 30, 2021, our cash, cash equivalents and marketable securities totaled $39.0 million.

We have experienced recurring losses since our inception. We incurred net losses of $12.3 million and $17.2 million for the nine months ended September 30, 2021 and 2020, respectively. We expect to continue to incur substantial negative cash flows from operations for at least the next several years as we work to increase market acceptance of our gammaCore therapy for the acute treatment of eCH, the prevention of cluster headache, and the preventive and acute treatment of migraine in adults and adolescents.

Our expected cash requirements for the next 12 months and beyond are largely based on the commercial success of our products. There are significant risks and uncertainties as to our ability to achieve these operating results, including as a result of the adverse impact on its headache business from the ongoing COVID-19 pandemic. These conditions raise substantial doubt about our ability to continue as a going concern.

We have historically funded our operations from the sale of our common stock. During the nine months ended September 30, 2021, we received net proceeds of approximately $25.7 million from such sales and as of September 30, 2021, our cash, cash equivalents and marketable securities totaled $39.0 million.

We believe that the substantial doubt of our ability to continue as going concern is alleviated based on proceeds received from recent offerings of our common stock. We believe our cash and marketable securities will enable us to fund our operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying financial statements are issued.

27

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We develop our products in the United States and sell those products into several countries. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Most of our sales in Europe are denominated in British Pound Sterling. As our sales in currencies other than the U.S. dollar increase, our exposure to foreign currency fluctuations may increase. In addition, changes in exchange rates also may affect the end-user prices of our products compared to those of our foreign competitors, who may be selling their products based on local currency pricing. These factors may make our products less competitive in some countries.

If the U.S. dollar uniformly increased or decreased in strength by 10% relative to the currencies in which our sales were denominated, our net income would have correspondingly increased or decreased by an immaterial amount for the nine months ended September 30, 2021.

Our exposure to market interest rate risk is confined to our cash and cash equivalents and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we may maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. The securities in our investment portfolio, if any, are not leveraged, are classified as available for sale and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our cash equivalents, we do not believe that an increase in market rates would have any material negative impact on interest income recognized in our statement of operations. We have no investments denominated in foreign currencies and therefore our investments are not subject to foreign currency exchange risk. We contract with CROs, investigational sites, suppliers and other vendors in Europe and internationally. We are subject to fluctuations in foreign currency rates in connection with these agreements. We do not hedge our foreign currency exchange rate risk.

All of the potential changes noted above are based on sensitivity analyses performed on our financial position as of September 30, 2021.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms, and that such information is accumulated and communicated to us, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision making regarding required disclosure. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and we apply our judgment in evaluating whether the benefits of the controls and procedures that we adopt outweigh their costs.

As required by Rule 13a-15(b) of the Exchange Act, an evaluation as of September 30, 2021 was conducted under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of September 30, 2021 were effective for the purposes stated above.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the three months ended September 30, 2021 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

28

PART II— OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
On July 8, 2019 and August 1, 2019, purported stockholders of our company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to our company, the defendants included present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for our IPO; and two of our stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which proceeded under Docket No. SOM-L 000876-19. Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased our common stock in our IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees. On October 31, 2019, the Company and the other defendants filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020 the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court - Appellate Division. The appeal was argued on September 27, 2021. On October 8, 2021, the Appellate Division issued an order reversing the decision of the Superior Court. The case has been remanded to the Superior Court for oral argument on the motion to dismiss or the alternative stay.
On September 26, 2019 and October 31, 2019, purported stockholders of our company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to our company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for our IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased our common stock in our IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each alleged that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints sought unspecified compensatory damages, interest, costs and attorneys’ fees.
In the Turnofsky case, on November 25, 2019, several plaintiffs and their counsel moved to be selected as lead plaintiff and lead plaintiff’s counsel. On April 24, 2020, the Court granted the motion of Carole Tibbs and the firm Bragar, Eagel & Squire, P.C. On July 17, 2020 the plaintiffs filed an amended complaint in Turnofsky. In addition to the prior claims, the amended complaint adds an additional director defendant and two investors as defendants, adds a claim against the Company and the underwriters for violating Section 12(a)(2) of the Securities Act. On September 15, 2020, the Company and the other defendants filed a motion to dismiss the amended complaint for failure to state a claim. On November 6, 2020, the plaintiffs filed their opposition to the motion to dismiss. The Company and the other defendants filed reply papers in support of the motion on December 7, 2020. Argument of the motion to dismiss occurred on June 18, 2021. On August 13, 2021, the Court dismissed the amended complaint with leave to re-plead. On October 4, 2021, the plaintiffs filed a second amended complaint. The parties are participating in a non-binding mediation with JAMS. A session with the JAMS mediator occurred on March 30, 2021.
The Priewe case was voluntarily dismissed on February 19, 2020.

29

On March 4, 2021, purported stockholder Richard Martz brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Richard Maltz, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al., Case 3:21-cv-04135. The defendants include present and past directors and officers of the Company. The plaintiff purports to pursue derivative claims on behalf of the Company in connection with the IPO and actions occurring between the IPO and September 25, 2019. The complaint alleges that demand on the board of directors is excused. The complaint purports to allege claims against the defendants for violating Section 14(a) of the Exchange Act, breaching fiduciary duties, unjust enrichment and waste of corporate assets. The complaint also purports to allege claims for contribution in connection with the Turnofsky case described above, pursuant to Section 11(f) of the Securities Act and Sections 10(b) and 21D of the Exchange Act. The complaint seeks unspecified compensatory damages, interest, costs and attorneys’ fees; declaratory relief; and an order requiring changes to corporate governance and internal procedures and a vote on proposed amendments to the Bylaws and Certificate of Incorporation.
On March 8, 2021, purported stockholder Erin Yuson brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Erwin Yuson, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al., Case 3:21-cv-04481. The defendants include present and past directors and officers of the Company. The plaintiff purports to pursue derivative claims on behalf of the Company in connection with a 2019 proxy statement and actions occurring from the IPO through September 25, 2019. The complaint alleges that demand on the board of directors is excused. The complaint purports to allege claims against the defendants for violating Section 14(a) of the Exchange Act and breaching fiduciary duties. The complaint seeks unspecified compensatory damages, interest, costs and attorneys’ fees; declaratory relief; and an order requiring changes to corporate governance and internal procedures and a vote on proposed amendments to the Bylaws and Certificate of Incorporation.
The plaintiffs in the Maltz and Yuson derivative actions agreed to consolidate and stay those actions. The actions are stayed until and through the resolution of any motion for summary judgment in the Turnofsky federal securities class action. A stipulation to that effect was filed by the plaintiffs on April 14, 2021 and ordered by the court on April 30, 2021.
We intend to continue to vigorously defend ourselves in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, we are unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, we have not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgments or settlements that could adversely affect our financial condition.

30

Item 1A.
RISK FACTORS

You should carefully consider the following risk factors, in addition to the other information in this report on Form 10-Q, including the section of this report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report on Form 10-Q occurs, our business, operating results and financial condition could be seriously harmed. This report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report. The risk factor set forth below contains changes to the similarly titled risk factor included in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 11, 2021.

Risks Related to COVID-19

The coronavirus pandemic could have a significant negative impact on our business, revenues, financial condition and results of operations.

The persistence of the coronavirus pandemic has severely depressed the level of economic activity around the world. Many businesses and governments have taken preventative or protective actions, including mandatory COVID-19 vaccinations for employees, restrictions on travel and business operations, and advising or requiring individuals to limit or forego their time outside of their homes. As a result of those employees who choose not to receive a vaccination, there may be changes in the workforce. Temporary closures of many businesses have been ordered and numerous other businesses have temporarily closed voluntarily. Further, individuals' ability to travel has been curtailed through mandated travel restrictions, voluntary or mandated closures of travel-related businesses, as well as quarantines, shelter-in-place/stay-at-home and social distancing orders.

This coronavirus pandemic has also impacted, and may continue to impact, our headquarters, manufacturing, and warehousing and distribution facilities, as well as those of our third-party vendors, including through the effects of facility closures, employee furloughs, reductions in operating hours, staggered shifts and other social distancing efforts, labor shortages, decreased productivity and unavailability of materials or components. For example, we have limited access to our New Jersey office as a result of state-imposed restrictions. Furthermore, the recent Biden administration’s executive order requiring all on-site and remote federal employees, contractors and sub-contractors to be vaccinated against COVID-19 or receive an approved medical or religious exemption by December 8, 2021 may apply to us because of our Federal Supply Schedule Medical Equipment and Supply contract. Failure to comply with the executive order could lead to loss of the contract, which could have a material adverse effect on our business, revenues, financial condition and results of operations. In light of the executive order, we have implemented a mandatory COVID-19 vaccination policy for all employees. All of our U.S. employees had to provide proof of vaccination by November 1, 2021, subject to medical and religious exemptions. To the extent an employee qualifies for a medical or religious exemption, we will collaborate with the exempt employee to explore reasonable accommodation options that may permit the employee to perform the essential functions of their job without being vaccinated. We will be unable to accommodate an employee’s exemption request if such accommodation would prevent an employee from performing the essential functions of their job, or would result in undue hardship, which includes, but in not limited to, a risk of harm to others. There can be no assurance that this policy will not have an adverse effect on our recruitment and retention of, and relations with our employees. The coronavirus pandemic may also impact our ability to sell our product, ship our product on a timely basis and may increase our costs.

The spread of coronavirus has also caused us to modify our business practices (including a mandatory COVID-19 vaccine policy, social distancing practices, requiring non-essential production related team members to work remotely where possible, restricting business travel, cancelling certain events, and limiting visitor access to our facilities), and we may take further actions as may be required by government authorities or that we determine are necessary or advisable. Work-from-home and other measures introduce additional operational risks, including cybersecurity risks, and have affected the way we conduct our business, which could have an adverse effect on our operations. There is no certainty that such measures will be sufficient to mitigate the risks posed by the virus, and illness and workforce disruptions could lead to unavailability of key personnel and harm our ability to perform critical functions. In addition, work-from-home and related business practice modifications present significant challenges to maintaining our corporate culture, including employee engagement and productivity, both during the immediate pandemic crisis and as we make additional adjustments in the eventual transition from it. Implementing new business practices in order to protect employees, vendors and other parties with whom we interact may result in increased costs. Furthermore, even if we follow what we believe to be best practices, there can be no assurance that our measures will prevent the transmission of COVID-19 between employees. Any incidents of actual or perceived transmission may expose us to liability claims, adversely impact employee productivity and morale, and result in negative publicity and reputational harm.

31

Additionally, our sales and marketing efforts are, and may from time to time be, adversely affected by protocols for screening and restricting outside visitors and vendors that have been adopted by the Department of Veterans Affairs, commercial prescribers and other third parties. Officially imposed quarantines and self-quarantines could also interfere with patients’ ability to see a health care provider and obtain our gammaCore therapy.

The degree to which coronavirus impacts our results will continue to depend on future developments that are highly uncertain and cannot be predicted, including, without limitation, the timing, extent, trajectory and duration of the pandemic, the development, rollout and availability of effective treatments and vaccines, the imposition of protective public safety measures, and how quickly and to what extent normal economic and operating conditions can resume, if at all. These uncertainties may result in delays or modifications to our plans, initiatives and results.

For the reasons set forth above and other reasons that may come to light due to the coronavirus outbreak and any associated protective or preventative measures, we are unable to reasonably estimate coronavirus’ impact to our business, revenues, financial condition and results of operations. We are similarly unable to predict the degree to which the pandemic impacts our customers, suppliers, vendors, capital markets, and other partners, and their financial conditions, but a material effect on these parties could also adversely affect us.

The impact of coronavirus could also exacerbate other risks discussed below, which could in turn have a material adverse effect on us. Developments related to coronavirus have been rapidly changing, and additional impacts and risks may arise that we are not aware of or able to appropriately respond to currently.

Our ability to market gammaCore Sapphire CV under the EUA may be adversely affected to the extent that (i) the coronavirus pandemic subsides, regardless of whether or not the EUA is terminated, revoked or expires, and (ii) other treatments or vaccines for coronavirus are developed and made available. Furthermore, there are a number of preventative vaccines in development with two having received an Emergency Use Authorization approval and others potentially nearing regulatory approval. Additionally, the United States and other countries around the world have recently begun to approve and commence distributing COVID-19 vaccines in their jurisdictions. The broad distribution of COVID-19 vaccines may reduce demand for gammaCore Sapphire CV treatment as it may no longer be considered medically necessary.

More generally, in the future, our business, financial results, and financial condition may be negatively impacted by the effects of other disease outbreaks, epidemics, pandemics, or similar widespread public health concerns.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

(a) Not applicable.

(b) Not applicable.

32

Item 6. EXHIBITS

Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).

Exhibit Number |  | Description
31.1* |  | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* |  | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1** |  | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2** |  | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS |  | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* | Filed herewith.

** | Furnished herewith.

33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | Company Name
Date: November 4, 2021 |  | By: | /s/ DANIEL S. GOLDBERGER
|  |  | Daniel S. Goldberger
|  |  | Chief Executive Officer (Principal Executive Officer)
Date: November 4, 2021 |  | By: | /s/ BRIAN M. POSNER
|  |  | Brian M. Posner
|  |  | Chief Financial Officer (Principal Financial and Accounting Officer)

34